Last reviewed · How we verify
NCT07316361: GYNORYLAQ™
GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer
EARLY_PHASE1 trial testing • Biological: GYNORYLAQ-TM Personalized Neoantigenic Peptide Vaccine in Endometrial Carcinoma in 40 participants. Enrolling by invitation.
2 December 2029
Quick facts
| Lead sponsor | Biogenea Pharmaceuticals Ltd. |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 2 February 2026 |
| Primary completion | 2 December 2029 |
| Estimated completion | 2 December 2031 |
| Sites | 1 location across Greece |
Drugs / interventions tested
- • Biological: GYNORYLAQ-TM Personalized Neoantigenic Peptide Vaccine — full drug profile →
Conditions studied
- Endometrial Carcinoma — all drugs for Endometrial Carcinoma →
- Endometrial Carcinoma Stage III — all drugs for Endometrial Carcinoma Stage III →
Sponsor
Biogenea Pharmaceuticals Ltd. — full company profile →
Who can join
Eligibility, any sex, with Endometrial Carcinoma or Endometrial Carcinoma Stage III. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
GYNORYLAQ-VLINIVAL is an Early Phase I, non-randomized, single-arm, open-label clinical trial enrolling 40 patients with high-risk or recurrent endometrial carcinoma. All participants receive GYNORYLAQ-TM, a personalized neoantigenic peptide vaccine generated by the GYNORYLAQ-EC™ quantum-classical engine, in combination with systemic and supportive drug regimens that are individually selected and prescribed by the treating medical oncologist, Dr Emmanouelides Christos, according to contemporary standards of care and the clinical status of each patient. Only the GYNORYLAQ-TM vaccine is considered investigational within this protocol; all concomitant drugs (including antineoplastic agents and supportive care medications) are non-investigational, chosen and adjusted at the discretion of Dr Emmanouelides Christos. The primary objectives are to evaluate the safety/tolerability of GYNORYLAQ-TM in this real-world therapeutic context and the feasibility of quantum-guided, GMP-grade personalized vaccine manufacture. Secondary and exploratory objectives characterize vaccine-induced T-cell immunity and explore correlations between quantum/physics-based scores and clinical/immunologic outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07316361
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Endometrial Carcinoma
Currently open trials in the same condition.
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07062016 — Molecular and ctDNA Characterization of High-Risk Endometrial Cancer · recruiting
- NCT07407959 — Screening and Staging of Benign vs Malignant Pelvic Abnormalities · recruiting
- NCT06855706 — An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV · NA · recruiting
- NCT06632431 — Clinicopathological Analysis of Endometrial Carcinoma in the View of Old and New International Federation of Gynecology · recruiting
Other Biogenea Pharmaceuticals Ltd. trials
Trials by the same sponsor.
- NCT07328087 — COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer · EARLY_PHASE1 · recruiting
- NCT07285434 — Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularl · EARLY_PHASE1 · enrolling by invitation
- NCT07077616 — Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patient · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07316361 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Biogenea Pharmaceuticals Ltd.
- Last refreshed: 7 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07316361.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing